Bladder Cancer Clinical Trial
Official title:
Serum Metadherin mRNA Expression in Bladder Cancer
The study aims to study alterations of MTDH gene expression in the serum of bladder cancer
patients compared to control group to evaluate its role as a marker for diagnosis.
,to compare the diagnostic accuracy of MTDH with the previously used marker Bladder
Cancer-Specific Antigen-1 (BLCA-1 in the serum of bladder cancer patients .
and to study correlation between expression of the metadherin gene and serum level of BLCA-1,
and clinical and histopathological staging in patients with bladder cancer
Urinary bladder cancer (BC) is the ninth most common cancer worldwide. It is the fifth most
common malignancy in males and seventeenth most common in females.
In Egypt, bladder cancer represents a massive health burden where it is one of the commonest
cancers representing 6.9% in both sexes and 10.7% among men. Its distribution is 8.8% in
lower Egypt, 14.2% in middle Egypt and 12.6% in upper Egypt.Almost 50% of patients will
experience recurrence of their disease within 4 years of their initial diagnosis.The
prognosis of bladder cancer is poor as a result of highly invasive properties of tumour
cells.
The optimal treatment selection depends on early diagnosis as well as accurate staging and
grading.Currently there is a need for new molecular bio markers that can help clinicians to
identify patients requiring early, aggressive treatment.
Metadherin (MTDH) is an oncogene known as Astrocytic elevated gene-1(AEG-1).It was firstly
identified in 2002 at fetal astrocytes of persons exposed to HIV-1 and then known as a vital
oncogene mediating carcinogenesis,prognosis,invasion and cancer metastasis. AEG-1 expression
is raised in bladder cancer tissues relative to normal tissues, and serves as a poor
prognostic factor.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT06034015 -
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of APL-1501 Extended Release (ER) Capsules Compared to APL-1202 Immediate Release (IR) Tablets in Healthy Volunteers
|
Phase 1 | |
| Recruiting |
NCT04235764 -
En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device
|
||
| Completed |
NCT02371447 -
VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04081246 -
Transurethral Modified En Bloc Resection For Large Bladder Tumours.
|
N/A | |
| Recruiting |
NCT06059547 -
Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer
|
Phase 2 | |
| Terminated |
NCT04779489 -
Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer
|
N/A | |
| Not yet recruiting |
NCT04493489 -
Propranolol Adjuvant Treatment of Bladder Cancer
|
Phase 2 | |
| Completed |
NCT03520231 -
Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases
|
Phase 2 | |
| Recruiting |
NCT04537221 -
Nordic Cystectomy Study III - Transfusion
|
||
| Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
| Completed |
NCT01955408 -
Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment
|
N/A | |
| Completed |
NCT04487457 -
Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
|
||
| Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
| Recruiting |
NCT05562791 -
A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer
|
Phase 1 | |
| Completed |
NCT00199849 -
NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
|
Phase 1 | |
| Completed |
NCT02781428 -
To Detect the Sensitivity of the UroMark Assay
|
||
| Recruiting |
NCT04738630 -
Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer
|
Phase 2 | |
| Completed |
NCT03980041 -
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
Phase 2 | |
| Active, not recruiting |
NCT03978624 -
Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer
|
Phase 2 | |
| Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A |